<DOC>
	<DOCNO>NCT00987987</DOCNO>
	<brief_summary>The investigator previously show depletion CD4+CD25+FoxP3+ regulatory T cell ( Treg ) enhance alloreactivity T lymphocytes , attest accelerated GVHD allogeneic hematopoietic stem cell transplantation ( HSCT ) mouse . The investigator thus propose clinical trial test whether Treg-depleted donor lymphocytes infusion ( dDLI ) could induce improve graft-versus-tumor ( GVT ) effect patient refractory standard DLI ( stdDLI ) treatment relapse HSCT .</brief_summary>
	<brief_title>Amplifying Graft-Versus-Tumor Effect Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion</brief_title>
	<detailed_description>We previously show depletion CD4+CD25+FoxP3+ regulatory T cell ( Treg ) enhance alloreactivity T lymphocytes , attest accelerated GVHD allogeneic hematopoietic stem cell transplantation ( HSCT ) mouse . We thus propose clinical trial test whether Treg-depleted donor lymphocytes infusion ( dDLI ) could induce improve graft-versus-tumor ( GVT ) effect patient refractory standard DLI ( stdDLI ) treatment relapse HSCT . dDLI administer failure 1 several previous stdDLI least 107 CD3+ cells/kg , define minimal follow-up 2 month last injection . The absence previous clinical manifestation GVHD require include . To prepare dDLI , CD25+ Treg deplete donor leukaphereses use anti-CD25 magnetic microbeads CliniMACS device ( MYLTENYI ) . In order evidence potential effect dDLI , dDLI cell dose adjust equal maximal cell dose previously receive stdDLI . No comparison plan analysis .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Hematological malignancy except chronic myeloid leukaemia . Previous allogeneic hematopoietic stem cell transplantation . Relapse diagnose molecular , cytogenetic , cytological level . Failure previous stdILD inclusion first intention progressive disease . Age &gt; 18 year &lt; 70 year time inclusion . Performance status consider score ECOG &lt; 2 . Life expectation 1monthold superior . Signed write informed consent . Negative HCG 7 day precede inclusion woman age procreation . Membership French national insurance . Chronic myeloid leukemia Grade &gt; II acute GVHD chronic extensive GVHD time inclusion . Patient receive immunosuppressive treatment GVHD treatment time inclusion . Dysfunction liver ( ALAT/ASAT &gt; 5 N , bilirubin &gt; 50 ÂµM ) , renal function ( creatinine clearance &lt; 30 ml / min ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>hematological malignancy</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>donor lymphocyte infusion</keyword>
	<keyword>antitumor immunotherapy</keyword>
	<keyword>graft-versus-tumor effect</keyword>
	<keyword>regulatory T cell</keyword>
	<keyword>adult</keyword>
</DOC>